Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2016

Open Access 01-12-2016 | Research article

Diabetes screening intervals based on risk stratification

Authors: Sachiko Ohde, Emily McFadden, Gautam A. Deshpande, Hiroshi Yokomichi, Osamu Takahashi, Tsuguya Fukui, Rafael Perera, Zentaro Yamagata

Published in: BMC Endocrine Disorders | Issue 1/2016

Login to get access

Abstract

Background

Guidelines for frequency of Type 2 diabetes mellitus (DM) screening remain unclear, with proposed screening intervals typically based on expert opinion. This study aims to demonstrate that HbA1c screening intervals may differ substantially when considering individual risk for diabetes.

Methods

This was a multi-institutional retrospective open cohort study. Data were collected between April 1999 to March 2014 from one urban and one rural cohort in Japan. After categorization by age, we stratified individuals based on cardiovascular disease risk (Framingham 10-year cardiovascular risk score) and body mass index (BMI). We adapted a signal-to-noise method for distinguishing true HbA1c change from measurement error by constructing a linear random effect model to calculate signal and noise of HbA1c. Screening interval for HbA1c was defined as informative when the signal-to-noise ratio exceeded 1.

Results

Among 96,456 healthy adults, 46,284 (48.0%) were male; age (range) and mean HbA1c (SD) were 48 (30–74) years old and 5.4 (0.4)%, respectively. As risk increased among those 30–44 years old, HbA1c screening intervals for detecting Type 2 DM consistently decreased: from 10.5 (BMI <18.5) to 2.4 (BMI > 30) years, and from 8.0 (Framingham Risk Score <10%) to 2.0 (Framingham Risk Score ≥20%) years. This trend was consistent in other age and risk groups as well; among obese 30–44 year olds, we found substantially shorter intervals compared to other groups.

Conclusion

HbA1c screening intervals for identification of DM vary substantially by risk factors. Risk stratification should be applied when deciding an optimal HbA1c screening interval in the general population to minimize overdiagnosis and overtreatment.
Appendix
Available only for authorised users
Literature
2.
go back to reference American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37 Suppl 1:S14–80.CrossRef American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37 Suppl 1:S14–80.CrossRef
3.
go back to reference Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45–74 years of age. Diabetes Care. 2005;28(2):307–11.CrossRefPubMed Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45–74 years of age. Diabetes Care. 2005;28(2):307–11.CrossRefPubMed
4.
go back to reference Lin KW, Chang C. Screening for type 2 diabetes mellitus in adults. Am Fam Physician. 2009;80(10):1141.PubMed Lin KW, Chang C. Screening for type 2 diabetes mellitus in adults. Am Fam Physician. 2009;80(10):1141.PubMed
5.
go back to reference Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.CrossRefPubMed Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.CrossRefPubMed
6.
go back to reference Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan BT, Davies MJ. The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010;27(8):887–95.CrossRefPubMed Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan BT, Davies MJ. The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010;27(8):887–95.CrossRefPubMed
7.
go back to reference NICE. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. 2012. NICE. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. 2012.
8.
go back to reference Chamnan P, Simmons RK, Forouhi NG, Luben RN, Khaw KT, Wareham NJ, Griffin SJ. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the european prospective investigation of cancer-norfolk cohort: implications for preventive strategies. Diabetes Care. 2011;34(4):950–6.CrossRefPubMedPubMedCentral Chamnan P, Simmons RK, Forouhi NG, Luben RN, Khaw KT, Wareham NJ, Griffin SJ. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the european prospective investigation of cancer-norfolk cohort: implications for preventive strategies. Diabetes Care. 2011;34(4):950–6.CrossRefPubMedPubMedCentral
9.
go back to reference Ebell M, Herzstein J. Improving quality by doing less: overscreening. Am Fam Physician. 2015;91(1):22–4.PubMed Ebell M, Herzstein J. Improving quality by doing less: overscreening. Am Fam Physician. 2015;91(1):22–4.PubMed
10.
go back to reference Siu AL. US Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(11):861–8.CrossRefPubMed Siu AL. US Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(11):861–8.CrossRefPubMed
11.
go back to reference McDonald TJ, Warren R. Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. Diabetes Care. 2014;37(6):e135–6.CrossRefPubMed McDonald TJ, Warren R. Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. Diabetes Care. 2014;37(6):e135–6.CrossRefPubMed
12.
go back to reference American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25 Suppl 1:S21–4. American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25 Suppl 1:S21–4.
13.
go back to reference Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.
14.
go back to reference Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.CrossRefPubMed Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.CrossRefPubMed
15.
go back to reference Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375(9723):1365–74.CrossRefPubMed Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375(9723):1365–74.CrossRefPubMed
16.
go back to reference Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care. 2010;33(9):2016–7.CrossRefPubMedPubMedCentral Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care. 2010;33(9):2016–7.CrossRefPubMedPubMedCentral
17.
go back to reference D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation. 2008;117(6):743–53.CrossRefPubMed D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation. 2008;117(6):743–53.CrossRefPubMed
18.
go back to reference Kuusisto J, Laakso M. Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr Cardiol Rep. 2013;15:1–6.CrossRef Kuusisto J, Laakso M. Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr Cardiol Rep. 2013;15:1–6.CrossRef
19.
go back to reference Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–34.CrossRefPubMed Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–34.CrossRefPubMed
20.
go back to reference WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.CrossRef WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.CrossRef
21.
go back to reference Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia‐Oceania. Asia Pac J Clin Nutr. 2002;11(s8):S732–7.CrossRef Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia‐Oceania. Asia Pac J Clin Nutr. 2002;11(s8):S732–7.CrossRef
22.
go back to reference Bell KJ, Hayen A, Irwig L, Takahashi O, Ohde S, Glasziou P. When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ. 2013;346:f1895.CrossRefPubMed Bell KJ, Hayen A, Irwig L, Takahashi O, Ohde S, Glasziou P. When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ. 2013;346:f1895.CrossRefPubMed
23.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ, Coordinating Committee of the National Cholesterol Education P. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ, Coordinating Committee of the National Cholesterol Education P. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.CrossRefPubMed
24.
go back to reference Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb. 2014;21(8):784–98.CrossRefPubMed Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb. 2014;21(8):784–98.CrossRefPubMed
25.
go back to reference Stevens RJ, Oke J, Perera R. Statistical models for the control phase of clinical monitoring. Stat Methods Med Res. 2010;19(4):394–414.CrossRefPubMed Stevens RJ, Oke J, Perera R. Statistical models for the control phase of clinical monitoring. Stat Methods Med Res. 2010;19(4):394–414.CrossRefPubMed
26.
go back to reference Perera R, McFadden E, McLellan J, Lung T, Clarke P, Perez T, Fanshawe T, Dalton A, Farmer A, Glasziou P, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. 2015;19(100):1–402.CrossRef Perera R, McFadden E, McLellan J, Lung T, Clarke P, Perez T, Fanshawe T, Dalton A, Farmer A, Glasziou P, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. 2015;19(100):1–402.CrossRef
27.
go back to reference Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, Investigators LS. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148(9):656–61.CrossRefPubMed Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, Investigators LS. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148(9):656–61.CrossRefPubMed
28.
go back to reference Nanri A, Nakagawa T, Kuwahara K, et al. Development of risk score for predicting 3-year incidence of Type 2 diabetes: Japan Epidemiology Collaboration on Occupational Health Study. PLoS One. 2015;10(11):e0142779.CrossRefPubMedPubMedCentral Nanri A, Nakagawa T, Kuwahara K, et al. Development of risk score for predicting 3-year incidence of Type 2 diabetes: Japan Epidemiology Collaboration on Occupational Health Study. PLoS One. 2015;10(11):e0142779.CrossRefPubMedPubMedCentral
29.
go back to reference Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH, Williams DR, Wareham NJ, Griffin SJ. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia. 2011;54(2):312–9.CrossRefPubMed Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH, Williams DR, Wareham NJ, Griffin SJ. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia. 2011;54(2):312–9.CrossRefPubMed
30.
go back to reference Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380(9855):1741–8.CrossRefPubMedPubMedCentral Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380(9855):1741–8.CrossRefPubMedPubMedCentral
31.
go back to reference Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(11):765–76.CrossRefPubMed Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(11):765–76.CrossRefPubMed
32.
go back to reference Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8.
Metadata
Title
Diabetes screening intervals based on risk stratification
Authors
Sachiko Ohde
Emily McFadden
Gautam A. Deshpande
Hiroshi Yokomichi
Osamu Takahashi
Tsuguya Fukui
Rafael Perera
Zentaro Yamagata
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2016
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-016-0139-1

Other articles of this Issue 1/2016

BMC Endocrine Disorders 1/2016 Go to the issue